BeiGene and Immix ink collaboration agreement for IMX-110/tislelizumab cancer study
Aug. 27, 2021 8:47 AM ET By: Aakash Babu, SA News Editor
BeiGene (NASDAQ:BGNE) and Immix Biopharma announce a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a combination of IMX-110 and tislelizumab for the treatment of various solid tumors.
Under the terms of the agreement, ImmixBio will evaluate the combination of IMX-110 with tislelizumab in a Phase 1/2a trial in patients with advanced solid tumors.
“We have high hopes that IMX-110 in combination with tislelizumab could expand the population of cancer patients experiencing extended remissions,” ImmixBio CEO Ilya Rachman said.